"
Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer"
written by Wei Shi, Xinyue Wang, Xiwen Bi, Wen Xia, Jiajia Huang, Yanhong Su, Zhangzan Huang, Zhongyu Yuan,
published by
Journal of Cancer Therapy,
Vol.10 No.2, 2019
has been cited by the following article(s):
|
[1]
|
Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer
Scientific Reports,
2025
DOI:10.1038/s41598-025-12419-3
|
|
|
|
|
[2]
|
Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
Journal of Chemotherapy,
2024
DOI:10.1080/1120009X.2024.2342741
|
|
|
|
|
[3]
|
Chemotherapy Combined With Endocrine Therapy: Old Wine in a New Bottle?
Clinical Breast Cancer,
2024
DOI:10.1016/j.clbc.2024.08.018
|
|
|
|
|
[4]
|
Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Current Oncology,
2023
DOI:10.3390/curroncol30070454
|
|
|
|
|
[5]
|
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
npj Breast Cancer,
2022
DOI:10.1038/s41523-022-00426-w
|
|
|
|
|
[6]
|
Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
Expert Review of Anticancer Therapy,
2020
DOI:10.1080/14737140.2020.1782200
|
|
|
|
|
[7]
|
Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer
Breast Cancer Management,
2019
DOI:10.2217/bmt-2019-0012
|
|
|
|